title: [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations].
abstract: In European Country, Canada, Australia and Brazil immunization program with conjugate meningococcal C, including universal vaccination of infants or toddlers, with a catch-up program up to 19 y in several areas, have been successful in reducing disease incidence through direct and indirect protection. In USA, quadrivalent conjugate vaccines targeting serogroups ACYW135 are used in programs of adolescent immunization at 10 and 15 years because serotype Y is frequent. A mass immunization campaign against serogroupe A disease with a conjugate vaccine is beginning in African belt of meningitis. Polysaccharide vaccines A, C or ACYW135 are used in travelers but quadrivalent conjugate vaccine, with larger targets, gives higher titers after booster and must be preferred. Some questions are pending: immunize before or after one year of age, a booster dose in adolescence and the routine use of quadrivalent conjugate vaccine in Europe if the incidence of serotype Y is growing.
authors.affiliation: Service de Pédiatrie, Maladies Infectieuses et Tropicales, Groupe Hospitalier Necker-Enfants Malades, 149, rue de Sèvres, 75743 Paris cedex 15, France. dominique.gendrel@nck.aphp.fr
authors.forename: D
authors.initials: D
authors.lastname: Gendrel
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D019049:Developed Countries / Q000706:statistics & numerical data; D003906:Developing Countries / Q000706:statistics & numerical data; D005602:France / Q000453:epidemiology; D014943:Global Health; D006291:Health Policy / Q000191:economics / Q000639:trends; D006801:Humans; D007117:Immunization, Secondary / Q000191:economics; D007223:Infant; D032541:Mass Vaccination / Q000191:economics; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000517:prevention & control*; D008589:Meningococcal Infections / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000191:economics; D009345:Neisseria meningitidis / Q000145:classification / Q000302:isolation & purification / Q000472:pathogenicity*; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome; D014611:Vaccination / Q000191:economics; D018074:Vaccines, Conjugate / Q000008:administration & dosage
chemical_list: D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate